MGNX — MACROGENICS INC (Healthcare >> Biotechnology)
MGNX FAQ
What is MGNX's P/E ratio?
MACROGENICS INC (MGNX) currently trades at a P/E ratio of 16.06.
What is MGNX's ROE?
MACROGENICS INC reports a Return on Equity (ROE) of -331.91%.
What is MGNX's dividend yield?
MACROGENICS INC offers a dividend yield of 0.00%.
What is MGNX's Deepscope Quality Score?
Deepscope rates MGNX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MGNX?
Deepscope's AI Timing Score for MGNX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MGNX belong to?
MACROGENICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.91
Price
-0.34
(-8.00%)
Day Change
|
|
|---|
MGNX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.91 |
| PBV / Sector |
12.74 / 4.63
|
| Earning Per Share | -1.02 |
| PE / Sector |
16.06 / 17.43
|
| PEG or PE/Growth / Sector |
0.09 / 0.53
GREAT
|
| Average 1M Daily Value |
5.87 M
GREAT
|
| Average 1W Daily Value |
2.27 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MGNX |
| Name | MACROGENICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 63.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 270.14 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850
Phone: 301 251 5172
Website: https://www.macrogenics.com
Employees: 293
Sector: Healthcare >> Biotechnology
Description: MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google